Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | TP53 | P04637 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3468587 | 0.82 | HRH3 (1.00) | HRH3MAPTTP53SMN1; SMN2HTT | |
| SCHEMBL3468738 | 0.81 | HRH3 (0.98) | HRH3MAPTTP53SMN1; SMN2HTT | |
| SCHEMBL3468782 | 0.81 | HRH3 (0.55) | HRH3MAPTTP53SMN1; SMN2HTT | |
| SCHEMBL3468779 | 0.78 | HRH3 (0.73) | HRH3MAPTTP53SMN1; SMN2HTT | |
| SCHEMBL3468608 | 0.78 | HRH3 (0.41) | HRH3MAPTSMN1; SMN2LMNANPC1 | |
| SCHEMBL3468573 | 0.77 | HRH3 (0.82) | HRH3MAPTTP53SMN1; SMN2HTT | |
| SCHEMBL3468785 | 0.77 | PARP1 (0.42) | HRH3GRM2 | |
| SCHEMBL3468584 | 0.76 | HRH3 (0.69) | HRH3MAPTTP53SMN1; SMN2HTT | |
| SCHEMBL3468858 | 0.75 | HRH3 (1.00) | HRH3MAPTTP53SMN1; SMN2HTT | |
| SCHEMBL3469017 | 0.72 | NPC1 (0.65) | HRH3MAPTTP53SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | claimed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | disclosed |
| EP-1999120-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007110364-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007110364-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | HRH3 1/4885MAPT 1467/4885TP53 4576/4885 |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | HRH3 1/4885MAPT 1511/4885TP53 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.